Erica Suzan1, Elon Eisenberg, Roi Treister, May Haddad, Dorit Pud. 1. The Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Institute of Pain Medicine, Rambam Health Care Campus, Haifa, Israel. Erica.dol@gmail.com
Abstract
BACKGROUND: Opioids are the cornerstone therapy for the treatment of moderate to severe pain. Yet, unconfirmed evidence suggests that chronic exposure to opioids may cause hypersensitivity to pain, a phenomenon known as opioid-induced hyperalgesia (OIH). OBJECTIVES: The current preliminary prospective study was aimed to explore the relationship between experimental OIH and clinical opioid induced analgesia (OIA) in a model of experimental OIH in patients with chronic radicular pain using intermediate-term opioid therapy. STUDY DESIGN: Prospective evaluation SETTING: Interdisciplinary Pain Clinic at a referral Health Care Campus METHODS: Thirty patients with chronic neuropathic (radicular) pain were assessed prior to and following 4 weeks of an individually titrated dose of oral hydromorphone treatment (4-20 mg/d). The assessments included an evaluation of experimental OIH by testing for heat pain intensity and cold pain tolerance and an assessment of OIA by completing pain and disability questionnaires. RESULTS: Hydromorphone was found to induce hyperalgesia, as measured by an elevation of phasic heat pain intensity (P < 0.05). At the same time, hydromorphone caused significant clinical analgesic effects. There was a notable reduction in average daily pain scores (primary analgesic outcome) of 26 Visual Analog Scale (0-100) points. A significant negative correlation was found between OIH and all OIA measures (r = -0.389, P < 0.05 for the primary analgesic outcome). Hydromorphone dosage was positively correlated with OIH (P < 0.01, r = 0.467) and negatively correlated with OIA parameters (r = -0.592, P < 0.01 for the primary analgesia outcome). LIMITATIONS: The nonrandomized, open-label, prospective evaluation. CONCLUSION: A 4-week regimen of open-label hydromorphone therapy results in a dose-dependent OIH, which negatively correlates with its analgesic effect. Future randomized, controlled, and blinded studies are needed to verify these preliminary results.
BACKGROUND: Opioids are the cornerstone therapy for the treatment of moderate to severe pain. Yet, unconfirmed evidence suggests that chronic exposure to opioids may cause hypersensitivity to pain, a phenomenon known as opioid-induced hyperalgesia (OIH). OBJECTIVES: The current preliminary prospective study was aimed to explore the relationship between experimental OIH and clinical opioid induced analgesia (OIA) in a model of experimental OIH in patients with chronic radicular pain using intermediate-term opioid therapy. STUDY DESIGN: Prospective evaluation SETTING:Interdisciplinary Pain Clinic at a referral Health Care Campus METHODS: Thirty patients with chronic neuropathic (radicular) pain were assessed prior to and following 4 weeks of an individually titrated dose of oral hydromorphone treatment (4-20 mg/d). The assessments included an evaluation of experimental OIH by testing for heat pain intensity and cold pain tolerance and an assessment of OIA by completing pain and disability questionnaires. RESULTS:Hydromorphone was found to induce hyperalgesia, as measured by an elevation of phasic heat pain intensity (P < 0.05). At the same time, hydromorphone caused significant clinical analgesic effects. There was a notable reduction in average daily pain scores (primary analgesic outcome) of 26 Visual Analog Scale (0-100) points. A significant negative correlation was found between OIH and all OIA measures (r = -0.389, P < 0.05 for the primary analgesic outcome). Hydromorphone dosage was positively correlated with OIH (P < 0.01, r = 0.467) and negatively correlated with OIA parameters (r = -0.592, P < 0.01 for the primary analgesia outcome). LIMITATIONS: The nonrandomized, open-label, prospective evaluation. CONCLUSION: A 4-week regimen of open-label hydromorphone therapy results in a dose-dependent OIH, which negatively correlates with its analgesic effect. Future randomized, controlled, and blinded studies are needed to verify these preliminary results.
Authors: Peter M Grace; Keith A Strand; Erika L Galer; Daniel J Urban; Xiaohui Wang; Michael V Baratta; Timothy J Fabisiak; Nathan D Anderson; Kejun Cheng; Lisa I Greene; Debra Berkelhammer; Yingning Zhang; Amanda L Ellis; Hang Hubert Yin; Serge Campeau; Kenner C Rice; Bryan L Roth; Steven F Maier; Linda R Watkins Journal: Proc Natl Acad Sci U S A Date: 2016-05-31 Impact factor: 11.205
Authors: Ronald A Wasserman; Afton L Hassett; Steven E Harte; Jenna Goesling; Herbert L Malinoff; Daniel W Berland; Jennifer Zollars; Stephanie E Moser; Chad M Brummett Journal: Reg Anesth Pain Med Date: 2015 Nov-Dec Impact factor: 6.288
Authors: Timothy Y Mariano; Mascha van't Wout; Benjamin L Jacobson; Sarah L Garnaat; Jason L Kirschner; Steven A Rasmussen; Benjamin D Greenberg Journal: Pain Med Date: 2015-06-25 Impact factor: 3.750
Authors: R R Edwards; A J Dolman; E Michna; J N Katz; S S Nedeljkovic; D Janfaza; Z Isaac; M O Martel; R N Jamison; A D Wasan Journal: Pain Med Date: 2016-03-01 Impact factor: 3.750
Authors: Cathy Stannard; Helen Gaskell; Sheena Derry; Dominic Aldington; Peter Cole; Tess E Cooper; Roger Knaggs; Philip J Wiffen; R Andrew Moore Journal: Cochrane Database Syst Rev Date: 2016-05-24